"LabGenius Raises £35 Million in Funding for Drug Discovery and Expansion"
LabGenius Raises £35M in Series B Funding
LabGenius' Series B Funding
Key Highlights:
- Series B Funding: LabGenius raised £35 million in Series B funding, bringing its total funding to £58 million.
- Investors: M Ventures, Octopus Ventures, LG Corp, Atomico, Kindred Capital, Lux Capital, and Obvious Ventures participated in the funding round.
- Focus on Drug Discovery: LabGenius is a drug discovery company specializing in the development of next-generation therapeutic antibodies.
LabGenius' Target Market
- Pharmaceutical and Biotech Companies: LabGenius partners with large biotech and pharmaceutical companies to advance its drug discovery platform and therapeutic pipeline.
- Research and Development Institutions: Collaborations with academic institutions and research organizations for further advancements in drug discovery and development.
- Healthcare Providers and Patients: LabGenius aims to develop innovative biotherapeutics for the treatment of solid tumors, benefiting healthcare providers and patients.
What LabGenius Needs to Buy
- Research and Development Partnerships: Collaborations with academic institutions and research organizations for further advancements in drug discovery and development.
- Manufacturing and Supply Chain Solutions: Partnerships with manufacturers and suppliers to support the production and distribution of biotherapeutics.
- Regulatory and Compliance Services: Expertise in navigating regulatory requirements and ensuring compliance in the development and commercialization of therapeutic antibodies.